At Virogin, we are at the forefront of developing novel oncolytic virotherapies. For every decision we make in the workplace, we think of the patients first. Oncolytic virotherapy is among the most promising agents to induce immunogenicity and overcome immune-suppressive barriers in so-called “cold tumors” or relapsed/refractory patient populations.